Teplizumab in Pediatric Stage 2 Type 1 Diabetes
← catalyst calendarNCT05757713 · readout in 8 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
20estimated
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-25 | actual | When the study began enrolling |
| Primary completion | 2026-08-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-27 | estimated | The whole study's end, after follow-up |
| First posted | 2023-03-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus, Type 1
Intervention
- Biological: teplizumab
Primary outcome
what the primary-completion date above is the date OFTreatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), TEAEs leading to withdrawal, and serious adverse events (SAEs)
measured Through 104 Weeks
Publications
- PMID 41196293 — linked by the registry
- PMID 37158990 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed